James D. Schaub
Net Worth

Last updated: 16 Dec 2021

What is James D. Schaub net worth?

The estimated net worth of Mr. James D. Schaub is at least $3,123,749 as of 16 Dec 2021. He owns shares worth $450,549 as insider and has received compensation worth at least $2,673,200 in RVL Pharmaceuticals plc.

What is the salary of James D. Schaub?

Mr. James D. Schaub salary is $668,300 per year as Executive Vice President & Chief Operating Officer in RVL Pharmaceuticals plc.

How old is James D. Schaub?

Mr. James D. Schaub is 43 years old, born in 1982.

What stocks does James D. Schaub currently own?

As insider, Mr. James D. Schaub owns shares in one company:

Company	Title	Shares	Price per share	Total value
RVL Pharmaceuticals plc (OSMT)	Executive Vice President & Chief Operating Officer	405,900	$1.11	$450,549

What does RVL Pharmaceuticals plc do?

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.